Mark Stejbach bought stock once, on Jan 5, 2026
Director at Indivior Pharmaceuticals, Inc., and 1 other company
SEC CIK 0001487937 · Filings on SEC.gov ↗
Mark Stejbach's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
5 filings since Jan 2017, newest first
Indivior Plc
Director
Alkermes Plc.
SVP, Chief Comm Off, Alks Inc
Alkermes Plc.
SVP, Chief Comm Off, Alks Inc
Alkermes Plc.
SVP, Chief Comm Off, Alks Inc
Alkermes Plc.
SVP, Chief Comm Off, Alks Inc
About Mark Stejbach
Mark P. Stejbach is an accomplished commercial biotech and pharmaceutical executive with over 35 years of experience spanning private startups to Fortune 100 companies.( He has held senior roles across a broad range of commercial functions in the industry.(
Stejbach serves as an Independent Non-Executive Director at Indivior PLC since 2021, with a tenure of approximately 2.3 years and annual compensation of US$110.10k.( On January 5, 2026, he acquired 775 shares of Indivior PLC (NASDAQ:INDV) at $35.3926 per share, totaling $27,429, through the Non-Executive Director Purchase Plan, bringing his direct ownership to 16,847 shares.( He also holds a position as Non-Executive Director at Nirsum Laboratories, Inc.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.